Search

Your search keyword '"R. Oneglio"' showing total 10 results
Start Over Author "R. Oneglio"
10 results on '"R. Oneglio"'

1. Treatment

Author

C. S. Goodwin, B. Worsley, E. Pillai, V. Willems, H. D. Janisch, H. Langmaack, P. Sanchez, M. Alcalde, A. Lancho, P. Carpintero, R. Garcia, J. M. Pajares, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. V. Iakovenko, K. Vogt, H. Hahn, I. H. Rehmann, M. Hedding-Eckerich, J. Blessing, G. M. Sobala, D. A. F. Lynch, B. Gallacher, M. F. Dixon, A. T. R. Axon, E. Bayerdörffer, G. Mannes, A. Sommer, W. Höchter, J. Weingart, R. Hatz, S. Miehlke, N. Lehn, G. Ruckdeschel, P. Dirschedl, M. Stolte, R. J. Adamek, M. Wegener, S. Birkholz, W. Opferkuch, G. H. Rühl, B. Wedmann, J. Labenz, E. Gyenes, G. H. R’hl, G. Börsch, R. Maieron, C. Rizzi, L. Zoratti, S. Andreoli, G. L. Da Broi, C. A. Beltrami, Zhuya Chengyl, Mou Yangiong, Hua Jiesong, Zhang Zhenhua, L. Bierti, E. G. Bolis, R. Di Battista, R. de Franchis, D. J. McAvinchey, M. Laurence, J. O’Riordan, M. Fantazi, M. Khawaja, E Bologna, M. Stroppiana, S. Peyre, R. Pulitano’, C. Sategna-Guidetti, E. Martin, T. Alarcön, J. C. Sanz, M. I. Jimonez, M. López-Brea, A. Burette, Y. Glupczynski, C. Deprez, F. Di Mario, M. Ferrana, G. Battaglia, P. Dotto, F. Vianello, G. A. Grasso, R. Fiocca, L. Villiani, O. Luinetti, A. Gianatti, R. Boldorini, M. Lazzaroni, G. Bianchi Porro, E. Trespi, M. Perego, C. Alvisi, B. Cesana, E. Solcia, R. P. H. Logan, R. R. Greaves, P. A. Gummett, M. M. Walker, Q. N. Karim, A. E. Duggan, J. H. Baron, J. J. Misiewicz, J. Lohmarm, L. H. H. Porst, J. Schönlebe, H. Riedel, F. Catalano, G. Rizzo, M. T. Ayoubi Khajekini, G. Branciforte, G. Inserra, A. Liberti, R. Suriani, C. Pallante, M. Ravizza, D. Mazzucco, D. Galliano, M. Malandrino, R. Oneglio, M. Colozza, E. Gaia, F. Sallio, D. Colozza, C. Grandis, G. B. Forte, M. E. Bottiglieri, R. Durasco, E. Grimaldi, P. Rocco, H. X. Xia, M. A. Daw, S. Sant, S. Beattie, C. T. Keane, C. A. O’Morain, H. Larsson, M. L. Berglund, P. Tessaro, R. Schiavon, M. G. Contini, T. Ton, L. Norberto, M. Cassaro, M. Rugge, M. Guido, R. Baffa, S. Gloriosa, F. Turatello, R. Naccarato, R. Collins, C. O’Moram, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, P. Malfertheiner, C. J. McCarthy, M. McDermott, D. Hourihane, C. O’Morain, M. T. Droy-Lefiax, B. Forestier, D. Guillomain, O. Plique, D. Brugmann, F. Mégraud, H. Lamouliatte, P. H. Bernard, R. Cayla, M. Mégraud, A. de Mascarel, A. Quintonl, A. McLaren, S. R. McDowell, A. A. McColm, C. O’Malley, J. Bagshaw, F. Bouffant, P. Marelli, L. Cellini, M. Campa, B. Dainelli, G. Soldani, M. del Tacca, G. Ferrini, G. Larcinese, N. Semperlotti, Gy. Molnar, A. Fzentmihalyi, A. Takats, G. Gero, J. Penyige, Gy. Mark, J. Martínez-Gómez, D. García-Novo, D. Acuña-Quinõs, M. Gimeno, S. Vigneri, R. Termini, A. Scialabba, G. Pisciotta, R. Gusmaroli, F. Milesi, P. Mule, M. Menegatti, C. Reale, J. Holten, and D. Vaira

Subjects
General Medicine
Published
1992
Full Text
View/download PDF

2. Abstract form for the Irish Journal of Medical Science v workshop on gastroduodenal pathology and Helicobacter pylori July 5th — 7th 1992 — Dublin, Ireland

Author

R. P. H. Logan, P. A. Gummett, M. M. Walker, Q. N. Karim, J. H. Baron, J. J. Misiewicz, G. Trieber, S. Walker, U. Klotz, A. Lozniewski, M. Weber, J. D. de Korwin, J. Floquet, M. C. Conroy, J. C. Burdin, G. A. Mannes, E. Bayerdörffer, W. Höchter, J. Weingart, W. Heldwein, A. Sommer, S. Müller-Lissner, W. Bomschein, S. Miehlke, M. Weinzierl, G. Ruckdeschel, H. von Wulffen, W. Köpcke, M. Stolte, S. J. Rune, T. Justesen, J. M. Hansen, T. G. Jensen, J. Eriksen, O. ø. Thomsen, J. Scheibel, O. Bonnevie, A. Bremmelgaard, M. Vilien, S. Knuhtsen, L. Elsborg, J. Hansen, K. Lauritsen, H. R. Wulff, D. Boixeda, S. Ballestero, R. Cantón, L. De Rafael, C. Martinm de Argila, M. J. Pozuelo, J. Sampedro, F. Baquero, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. M. Hirschl, G. Brandstätter, B. Dragosics, E. Hentschel, M. Kundi, M. L. Rotter, K. Schütze, M. Taufer, M Neri, D Susi, I Bovani, R Pindo, F. Cuccurullo, L. G. V. Coelho, M. C. F. Passos, Y. Chausson, W. L. S. Vieira, F. J. Castro, J. M. M. Franco, M. L. M. Fernandes, L. P. Castro, C. Jonas, E. De Koster, M. Van Gossum, M. Depierreux, M. Cheval, M. Deltenre, E. Schütz, B. Bethke, A. Lee, E. Hegedus, J. O’Rourke, H. Larsson, S. Sjöstedt, B. Veress, C. E. Nord, G. M. Sobala, R. George, D. Tompkins, J. Finlay, A. Manning, S. Sant, H. X. Xia, M. Daw, J. Gilvarry, C. T. Keane, C. O’Morain, M. A. Rubio, B. Hegarty, A. L. Blum, E. Sulser, O. Stadelmann, N. Munoz, E. Buiatti, J. Vivas, W. Oliver, E. Cano, S. Peraza, D. Castro, V. Sanchez, O. Andrade, M. Benz, G. L. Mendz, S. L. Hazell, K. S. Salmela, R. P. Roire, J. Hook-Nikanne, T. U. Kosunen, M. Salaspur, C. J. Luke, D. D. J. Reynolds, C. W. Penn, G. Bode, F. Mauch, H. Ditschuneit, P. Malfertheiner, Richard L. Ferrero, Labigne Agnes, K. A. Eaton, S. Krakowka, H. L. T. Mobley, Li-Tai Hu, P. A. Foxall, A. P. Moran, I. M. Helander, C. Altman, I. Sobhani, C. Vissugaire, M. Migrant, J. P. Etienne, P. Sommi, V. Ricci, R. Fiocca, E. Cova, N. Figura, M. Romano, K. J. Ivey, E. Solcia, U. Ventura, M. Nilius, S. Schieffer, K. J. Hengels, H. Jablonowski, G. Strohmeyer, M. D. Cabrai, A. J. A. Barbosa, G. F. Lima Hr., C. A. Oliveira, J. M. Polak, G. Oderda, L. Villani, F. Altare, I. Morra, L. Miserendino, N. Ansaldi, M. F. Dixon, J. I. Wyatt, A. T. R. Axon, S. Beattie, H. Hamilton, S. Shabib, E. Cutz, B. Drumm, P. Sherman, L. A. Noach, T. Rolf, N. B. Bosma, M. P. Schwartz, J. Oosting, E. A. J. Rauws, G. N. J. Tytgat, A. Andrew, G. Nardone, F. d’Ormiento, M. Pontillo, A. J. Lobo, J. S. Uff, C. N. M. McNulty, S. P. Wilkinson, R. Suriani, C. Pallante, M. Ravizza, D. Galliano, D. Sallio, M. Malandrino, R. Oneglio, M. Colozza, D. Mazzucco, E. Gaia, S. Eidt, P. Vincent, F. Gottrand, D. Turck, M. Lecomte-Houcke, H. Leclerc, F. Bonvicini, S. Pretolani, M. Baraldini, D. Cilla, S. Baldinelli, E. Bazocchi, P. Acampora, N. Careddu, E. Brocchi, G. Gasbarrini, M. Joubert, N. Bazin, D. Thiaucourt, E. Protte, C. Gissler, A. Duprez, P. Merlin, S. Forestier, J. Labenz, E. Gyenes, G. H. Rühl, G. Börsch, G. Daskalopoulos, J. Carrick, R. Lian, S. Wagner, J. Bleck, M. Gebel, W. Bär, M. Manns, H. Lamouliatte, P. H. Bernard, R. Cayla, G. Vialette, A. Quinton, F. Mégraud, M. Lemaire, A. Quinten, A. De Mascarel, P. Webb, D. Forman, T. Knight, A. Wilson, S. Graves, D. Newell, J. Elder, E. Tonelli, M. R. A. Gatte, G. C. Ghironzi, G. Giulianelli, K. B. Bamford, J. S. A. Collins, J. Bickley, B. T. Johnston, S. Potts, V. Boston, R. J. Owen, J. Sloan, L. Basso, S. Lawlor, J. Clune, H. Szelényi, G. Stohmeyer, G. Macedo, I. Iglésias, A. P. Chaves, A. Loureiro, P. H. Katelaris, F. Seow, B. Lin, J. Napoli, D. B. Hones, M. C. Ngu, Natalia S. Akopyantz, Nikolay O. Bukanov, T. Ulf Westblom, Douglas E. Berg, J. F. Nyst, P. Denis, M. Buset, M. De Reuck, H. Nielsen, L. P. Andersen, Sabine Birkholz, Ulrich Knipp, Claudia Nietzki, Wolfgang Opferkuch, J. E. Crabtree, P. Peichl, I. J. D. Lindly, K. Deusch, C. Seifirth, A. Funk, I. Dahie, K. Reut, M. Classen, P. Gionchetti, D. Vaira, M. Campieri, E. Bertinelli, M. Menegatti, A. Belluzzi, C. Briognola, M. Miglioli, L. Barbara, A. Di Tommaso, M. T. De Magistris, M. Bugnoli, R. Petracca, A. Covacci, S. Censini, R. Rappuoli, S. Abrignani, M. C. Territo, K. L. Smela, J. R. Reeve, T. D. Lee, J. H. Walsh, D. Armellini, Z. Y. Xiang, H. M. Mitchell, P. J. Hu, Y. Y. Li, Z. J. Wang, S. M. Zhao, Q. Liu, M. Chen, G. G. Du, M. I. Filipe, P. I. Reed, M. E. Craanen, P. Blok, W. Dekker, E. Colombo, D. Redaelli, M. Santangelo, M. Spinelli, F. Farinati, F. Valiante, G. Delia Libera, B. Germanà, R. Baffa, M. Rugge, F. Vianelo, F. Di Mario, Pentti Sipponen, T. Rokkas, G. Popotheodorou, N. Kaldgeropoulos, C. Deprez, P. Galand, J. G. Fox, P. Wishnok, J. C. Murphy, S. Tannenbaum, P. Correa, Julie Parsonnet, C. Macor, G. L. Da Broi, C. Avellinio, R. Reifen, I. Rasooly, M. E. Millson, K. Murphy, J. E. Thomas, E. J. Eastham, E. Malorgio, D. Dell’Olio, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, M. R. A. Gatto, R. Olivieri, R. F. Bayeli, L. Abate, L. De Gregorio, J. Aziz, E. Esposito, C. Basagni, R. Guilluy, M. Rousseau-Tsangaris, J. L. Brazier, Torkel Wadstiöm, Tadeusz Tyszkiewicz, Per Bergenzaun, Karin Olsson, C. Birac, F. Tall, M. Albenque, A. Labigne, F. Megraud, R. A. Feldman, J. Deeks, Y. Glupczynski, A. Burette, H. Goossens, C. Van den Boore, J. P. Butzler, S. Veldhuyzen van Zanten, L. Best, G. Benzanson, D. Haldane, S. Hazell, N. P. Mapstone, D. A. F. Lynch, P. Quirke, D. E. Taylor, N. Chang, M. Eaton, E. Stockdale, S. M. Salama, L. Thompson, A. Cockayne, R. C. Spiller, E. Leen, E. Sweeney, H. Klann, R. Hatz, W. Bornschein, T. Simon, A. Eimiller, F. Bolle, C. Schweikert, W. Köpeke, S. F. Moss, A. E. Bishop, J. Calam, R. J. Cahill, H. Xia, J. Solnick, and L. Tompkins

Subjects
0303 health sciences, medicine.medical_specialty, biology, 030306 microbiology, business.industry, General surgery, General Medicine, Helicobacter pylori, biology.organism_classification, language.human_language, Duodenal ulcer, 03 medical and health sciences, Irish, language, Medicine, Optometry, Gastritis, medicine.symptom, business, Medical science, 030304 developmental biology
Published
1992
Full Text
View/download PDF

3. Helicobacter pylori-positive duodenal ulcer: a long-term double-blind randomized study in patients healed with H2-receptor antagonists

Author

C. Pallante, M. Colozza, R. Suriani, M. Ravizza, G. Orso Giacone, M. Malandrino, R. Oneglio, P. Dusio, D. Mazzucco, M. Vajo, and E. Cardesi

Subjects
Adult, Male, medicine.medical_specialty, Randomization, medicine.drug_class, Peptic, Antibiotics, Placebo, Ranitidine, Gastroenterology, Disease-Free Survival, law.invention, Helicobacter Infections, Maintenance therapy, Histamine H2 receptor, Randomized controlled trial, Double-Blind Method, law, Recurrence, Internal medicine, Metronidazole, medicine, Organometallic Compounds, Humans, Life Tables, Aged, biology, Helicobacter pylori, business.industry, Remission Induction, General Medicine, Middle Aged, biology.organism_classification, Anti-Ulcer Agents, Infectious Diseases, Histamine H2 Antagonists, Doxycycline, Duodenal Ulcer, Gastritis, Drug Therapy, Combination, Female, Antacids, business
Abstract

Background.The NIH Consensus Conference in 1994 (1) concluded that all patients with peptic ulcr disease should be tested and treated for Helicobacter pylori and that further evaluation was needed for patients in remission. Materials and Methods.We evaluated in a double blind randomization 30 patients whose duodenal ulcers had been healed with H2-receptor antagonists and who remained in remission on maintenance therapy. After ulcer healing and the presence of H. pylori had been confirmed, these patients were randomized to receive eradication therapy or placebo and were followed for a mean period of 23 months. Results.Almost all patients receiving placebo had ulcer recurrence, whereas the patients treated with antibiotics demonstrate a low recurrence rate. Conclusion. These data suggest, for the first time to our knowledge, the importance of treating with antibiotics duodenal ulcer patients whose disease is in remission.

Published
1996

5. [Resistance to cephalosporin in hospital strains of the KES group]

Author

F, Granatiero, C, Grandis, M, Malandrino, and R, Oneglio

Subjects
Cross Infection, Serratia, Lactams, Species Specificity, Klebsiella, Enterobacter, Enterobacteriaceae Infections, Humans, Drug Resistance, Microbial, Anti-Bacterial Agents, Cephalosporins
Abstract

In our laboratory KES group bacteria account for about 11% of all strains isolated from in-patients and are responsible for serious infections. Their well known increasing tendency to become resistant to beta-lactams prompted us to the KES strains isolated in medical or surgical patients in 1986.87. 30 Klebsiella retrospectively review the susceptibility to antibiotics of strains out of 59 had been isolated in that period from patients previously treated with beta-lactams: no significant variation in resistance to cephalosporins, compared to the 29 strains from non treated patients, was noted. However in the treated group one strain of Klebsiella pneumoniae out of 24 showed resistance to ceftazidime and one of Klebsiella oxytoca was resistant both to cefotaxime (1 out of 16) and ceftriaxone (1 out of 12). 19 strains of Enterobacter spp. out of 32 had bees isolated from treated patients; a significant increase in resistance to 3rd generation cephalosporins (p less than 0.01), compared to the 13 strains isolated from non treated patients, was noted. Our findings suggest that it is advisable to review the in-use antibiotic policy keeping in mind the severity of the infections caused by KES group bacteria.

Published
1989

6. Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes

Author

C, Canavese, P, Stratta, A, Pacitti, G, Mangiarotti, M, Racca, R, Oneglio, and A, Vercellone

Subjects
Adult, Renal Dialysis, Fibrinolysis, Humans, Middle Aged, Hemorrhagic Disorders, Peritoneal Dialysis, Aged, Uremia
Abstract

In addition to a hemorrhagic diathesis, uremia is accompanied by a clotting tendency, caused by a marked fall in fibrinolytic capacity. Measurement of lysis time of whole blood diluted with phosphate and acetate buffers and of euglobulin lysis times showed that accumulation of inhibitors is primarily responsible. These probably belong to the class of small molecules abnormally retained in uremia. Hemodialysis (HD) offers the best method of correction, mainly because of better elimination of these inhibitors. In contrast, hemofiltration (HF) and, particularly, intermittent peritoneal dialysis (IPD) are much less effective. In IPD, protein loss via the peritoneum is also responsible for a loss of fibrinolytic activators, so that fibrinolysis becomes even poorer, exposing the patient to an increased risk of vascular complications.

Published
1982

7. Helicobacter pylori-positive duodenal ulcer: a long-term double-blind randomized study in patients healed with H2-receptor antagonists.

Author

Suriani R, Ravizza M, Pallante C, Mazzucco D, Cardesi E, Colozza M, Malandrino M, Oneglio R, Orso Giacone G, Dusio P, and Vajo M

Subjects
Adult, Aged, Antacids administration & dosage, Disease-Free Survival, Double-Blind Method, Doxycycline administration & dosage, Drug Therapy, Combination administration & dosage, Duodenal Ulcer etiology, Duodenal Ulcer microbiology, Duodenal Ulcer prevention & control, Female, Gastritis drug therapy, Helicobacter Infections drug therapy, Humans, Life Tables, Male, Metronidazole administration & dosage, Middle Aged, Organometallic Compounds administration & dosage, Recurrence, Remission Induction, Antacids therapeutic use, Anti-Ulcer Agents therapeutic use, Doxycycline therapeutic use, Drug Therapy, Combination therapeutic use, Duodenal Ulcer drug therapy, Gastritis complications, Helicobacter Infections complications, Helicobacter pylori, Histamine H2 Antagonists therapeutic use, Metronidazole therapeutic use, Organometallic Compounds therapeutic use, Ranitidine therapeutic use
Abstract

Background: The NIH Consensus Conference in 1994 (1) concluded that all patients with peptic ulcer disease should be tested and treated for Helicobacter pylori and that further evaluation was needed for patients in remission., Materials and Methods: We evaluated in a double blind randomization 30 patients whose duodenal ulcers had been healed with H2-receptor antagonists and who remained in remission on maintenance therapy. After ulcer healing and the presence of H. pylori had been confirmed, these patients were randomized to receive eradication therapy or placebo and were followed for a mean period of 23 months., Results: Almost all patients receiving placebo had ulcer recurrence, whereas the patients treated with antibiotics demonstrate a low recurrence rate., Conclusion: These data suggest, for the first time to our knowledge, the importance of treating with antibiotics duodenal ulcer patients whose disease is in remission.

Published
1996
Full Text
View/download PDF

8. [Resistance to cephalosporin in hospital strains of the KES group].

Author

Granatiero F, Grandis C, Malandrino M, and Oneglio R

Subjects
Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Microbial, Enterobacteriaceae Infections drug therapy, Humans, Lactams therapeutic use, Species Specificity, Cephalosporins pharmacology, Cross Infection microbiology, Enterobacter drug effects, Enterobacteriaceae Infections microbiology, Klebsiella drug effects, Serratia drug effects
Abstract

In our laboratory KES group bacteria account for about 11% of all strains isolated from in-patients and are responsible for serious infections. Their well known increasing tendency to become resistant to beta-lactams prompted us to the KES strains isolated in medical or surgical patients in 1986.87. 30 Klebsiella retrospectively review the susceptibility to antibiotics of strains out of 59 had been isolated in that period from patients previously treated with beta-lactams: no significant variation in resistance to cephalosporins, compared to the 29 strains from non treated patients, was noted. However in the treated group one strain of Klebsiella pneumoniae out of 24 showed resistance to ceftazidime and one of Klebsiella oxytoca was resistant both to cefotaxime (1 out of 16) and ceftriaxone (1 out of 12). 19 strains of Enterobacter spp. out of 32 had bees isolated from treated patients; a significant increase in resistance to 3rd generation cephalosporins (p less than 0.01), compared to the 13 strains isolated from non treated patients, was noted. Our findings suggest that it is advisable to review the in-use antibiotic policy keeping in mind the severity of the infections caused by KES group bacteria.

Published
1989

10. Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes.

Author

Canavese C, Stratta P, Pacitti A, Mangiarotti G, Racca M, Oneglio R, and Vercellone A

Subjects
Adult, Aged, Hemorrhagic Disorders etiology, Humans, Middle Aged, Uremia therapy, Fibrinolysis, Peritoneal Dialysis adverse effects, Renal Dialysis adverse effects, Uremia blood
Abstract

In addition to a hemorrhagic diathesis, uremia is accompanied by a clotting tendency, caused by a marked fall in fibrinolytic capacity. Measurement of lysis time of whole blood diluted with phosphate and acetate buffers and of euglobulin lysis times showed that accumulation of inhibitors is primarily responsible. These probably belong to the class of small molecules abnormally retained in uremia. Hemodialysis (HD) offers the best method of correction, mainly because of better elimination of these inhibitors. In contrast, hemofiltration (HF) and, particularly, intermittent peritoneal dialysis (IPD) are much less effective. In IPD, protein loss via the peritoneum is also responsible for a loss of fibrinolytic activators, so that fibrinolysis becomes even poorer, exposing the patient to an increased risk of vascular complications.

Published
1982

Catalog

Books, media, physical & digital resources
See catalog results